Incretin drugs as modulators of atherosclerosis
Atherosclerosis is a major underlying cause of ischemic heart diseases, ischemic stroke, and peripheral artery disease. Atherosclerotic plaque progression is characterized by chronic progressive inflammation of the arterial wall, endothelial cell dysfunction, and subendothelial lipoprotein retention. Incretin drugs, glucagon-like peptide-1 receptor (GLP-1R) agonists, and dipeptidyl peptidase-IV (DPP-IV) inhibitors, are promising anti-hyperglycemic agents used for the treatment of type 2 diabetes mellitus (T2DM).
Source: Atherosclerosis - Category: Cardiology Authors: Enrique Gallego-Colon, Wojciech Wojakowski, Tomasz Francuz Tags: Review article Source Type: research
More News: Cardiology | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Heart | Incretin Therapy | Ischemic Stroke | Peripheral Vascular Disease (PVD) | Stroke